Stockwatch: Big Pharma And Big Biotech Are The New Black
This article was originally published in Scrip
Unlike the temporary blips of the last year when pharmacy benefit manager Express Scripts Holding Corp. went to war with Gilead Sciences, Inc. on drug pricing, or Federal Reserve chair Yellen warned on the frothy valuations of early-stage biotech companies, this time it is different. Firstly it has lasted longer than previous pull-backs, secondly, like the stock market retrenchment that followed the tragedies of September 11 2001, there is no direct connection with life science stocks, and thirdly, the supposedly unrelated initiating factor – China's slowing economic growth and the bursting of its stock market bubble – was in temporary remission on Thursday and Friday last week but life science stocks still traded off on both days. This time I am afraid that the market means it and as generalists continue to rotate out of life sciences, there are reasons to believe that bigger is going to be better as the investors who are left focus on tangible investment attributes for a change.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.